GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » Cyclically Adjusted PS Ratio

Genmab AS (STU:GE9) Cyclically Adjusted PS Ratio : 9.39 (As of Jun. 02, 2025)


View and export this data going back to . Start your Free Trial

What is Genmab AS Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Genmab AS's current share price is €186.55. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €19.86. Genmab AS's Cyclically Adjusted PS Ratio for today is 9.39.

The historical rank and industry rank for Genmab AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:GE9' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.23   Med: 50.55   Max: 96.41
Current: 9.27

During the past years, Genmab AS's highest Cyclically Adjusted PS Ratio was 96.41. The lowest was 8.23. And the median was 50.55.

STU:GE9's Cyclically Adjusted PS Ratio is ranked worse than
66.53% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs STU:GE9: 9.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab AS's adjusted revenue per share data for the three months ended in Mar. 2025 was €10.345. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €19.86 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted PS Ratio Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.46 47.06 35.47 19.98 10.67

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.08 14.14 12.27 10.67 9.00

Competitive Comparison of Genmab AS's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


;
;

Genmab AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genmab AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=186.55/19.86
=9.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.345/120.2000*120.2000
=10.345

Current CPI (Mar. 2025) = 120.2000.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.381 100.300 0.457
201509 0.612 100.200 0.734
201512 1.262 99.800 1.520
201603 0.383 100.200 0.459
201606 0.761 100.600 0.909
201609 0.792 100.200 0.950
201612 1.888 100.300 2.263
201703 0.544 101.200 0.646
201706 1.706 101.200 2.026
201709 0.680 101.800 0.803
201712 2.279 101.300 2.704
201803 1.471 101.700 1.739
201806 1.094 102.300 1.285
201809 1.287 102.400 1.511
201812 2.619 102.100 3.083
201903 1.277 102.900 1.492
201906 1.657 102.900 1.936
201909 2.134 102.900 2.493
201912 6.184 102.900 7.224
202003 1.813 103.300 2.110
202006 11.100 103.200 12.928
202009 3.501 103.500 4.066
202012 4.966 103.400 5.773
202103 3.172 104.300 3.656
202106 3.972 105.000 4.547
202109 4.636 105.800 5.267
202112 4.906 106.600 5.532
202203 4.378 109.900 4.788
202206 6.365 113.600 6.735
202209 8.277 116.400 8.547
202212 12.137 115.900 12.587
202303 5.886 117.300 6.032
202306 8.530 116.400 8.808
202309 9.493 117.400 9.719
202312 10.921 116.700 11.249
202403 8.495 118.400 8.624
202406 11.103 118.500 11.262
202409 11.699 118.900 11.827
202412 11.072 118.900 11.193
202503 10.345 120.200 10.345

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab AS  (STU:GE9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genmab AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines